- About Us
- Our Clients
- Practice Areas
- Asia Pacific Law
- Bankruptcy, Insolvency & Restructuring
- Competition Law
- Corporate & Commercial
- Criminal & Extradition
- Environmental, Energy & Natural Resources
- Family Law
- First Nations & Aboriginal Law
- Intellectual Property
- Immigration Law
- International Trade Law
- Labour & Employment Law
- Litigation & Dispute Resolution
- Maritime Law
- Municipal Law
- Real Estate Law
- Taxation Law
- Wealth Management
- Wine Law
- Our People
- Global Services
- Students
- Careers
- News
- Contact Us
News
06 July 2011
James Hatton Advises on Stem Cell License Agreement for Pulmonary Hypertension
Farris partner James Hatton recently acted for Washington, DC-based United Therapeutics Corporation (Nasdaq:UTHR) in its exclusive worldwide license agreement with Haifa, Israel-based Pluristem Therapeutics Inc. (Nasdaq:PSTI). United Therapeutics will have the right to develop and commercialize Pluristem’s placental stem cells for the treatment of Pulmonary Hypertension.
Pluristem will receive an upfront payment of $7million and is eligible to receive regulatory milestone payments and other payments accumulating together with the upfront payment to a total of approximately $55 million and reimbursement of costs of its development and clinical activities. Following commercialization, United Therapeutics shall purchase commercial supplies from Pluristem at a specified margin over Pluristem’s cost. In addition, United Therapeutics will pay Pluristem specified royalties as a percentage from its gross profits generated from the developed product.
News
E-Newsletter
Sign up for our Email Newsletter to receive regular Farris updates: